Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting.

IF 4.3 3区 医学 Q1 UROLOGY & NEPHROLOGY American Journal of Nephrology Pub Date : 2024-09-02 DOI:10.1159/000541109
Rachel M Holden, Patrick A Norman, Andrew G Day, Samuel A Silver, Kristen K Clemens, Eduard Iliescu
{"title":"Vitamin D Status and Treatment in ESKD: Links to Improved CKD-MBD Laboratory Parameters in a Real-World Setting.","authors":"Rachel M Holden, Patrick A Norman, Andrew G Day, Samuel A Silver, Kristen K Clemens, Eduard Iliescu","doi":"10.1159/000541109","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Vitamin D insufficiency is common in patients who receive hemodialysis, yet there is no clear guidance regarding surveillance or treatment. We hypothesized that increasing 25(OH)D3 levels is associated with lower phosphate, parathyroid hormone (PTH), and alkaline phosphatase (ALP).</p><p><strong>Methods: </strong>Baseline 25(OH)D3 level was measured in all patients receiving in-center hemodialysis in June 2017. Laboratory parameters were measured every 6 (phosphate, calcium) or 12 weeks (25(OH)D3, PTH, ALP) until February 2021. In September 2018, a treatment algorithm of 50,000 IU weekly until sufficient followed by 50,000 IU monthly was suggested. Generalized linear mixed regression models including linear spline effects, a log link function, and random effects were used to examine the impact of increasing 25(OH)D3 levels on calcium, phosphate, ALP, and PTH.</p><p><strong>Results: </strong>Of 697 participants, 15% and 57% had vitamin D deficiency (25(OH)D3 &lt;25 nmol/L) and insufficiency (between 25 and 74 nmol/L). Incorporating up to 7,272 observations, increasing 25(OH)D3 was associated with significantly decreasing PTH for 25(OH)D3 levels between 25 and 75 nmol/L regardless of vitamin D treatment. In an interaction model, the negative slope between 25(OH)D3 and PTH remained significant beyond 75 nmol/L in the absence of calcitriol. Increasing 25(OH)D3 was associated with significantly decreasing phosphate for 25(OH)D3 levels between 25 and 75 nmol/L regardless of vitamin D treatment and below 25 nmol/L in values of untreated patients. Calcium increased across the spectrum of 25(OH)D3 regardless of vitamin D treatment. Overall, 0.2% of 25(OH)D3 levels exceeded 250 nmol/L and 2.1% of calcium levels exceeded the normal range.</p><p><strong>Conclusions: </strong>Vitamin D treatment in a real-world setting was safe and associated with lower PTH levels. Whether improved biochemical markers translate to a reduction in clinical endpoints warrants further study.</p>","PeriodicalId":7570,"journal":{"name":"American Journal of Nephrology","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541109","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Vitamin D insufficiency is common in patients who receive hemodialysis, yet there is no clear guidance regarding surveillance or treatment. We hypothesized that increasing 25(OH)D3 levels is associated with lower phosphate, parathyroid hormone (PTH), and alkaline phosphatase (ALP).

Methods: Baseline 25(OH)D3 level was measured in all patients receiving in-center hemodialysis in June 2017. Laboratory parameters were measured every 6 (phosphate, calcium) or 12 weeks (25(OH)D3, PTH, ALP) until February 2021. In September 2018, a treatment algorithm of 50,000 IU weekly until sufficient followed by 50,000 IU monthly was suggested. Generalized linear mixed regression models including linear spline effects, a log link function, and random effects were used to examine the impact of increasing 25(OH)D3 levels on calcium, phosphate, ALP, and PTH.

Results: Of 697 participants, 15% and 57% had vitamin D deficiency (25(OH)D3 <25 nmol/L) and insufficiency (between 25 and 74 nmol/L). Incorporating up to 7,272 observations, increasing 25(OH)D3 was associated with significantly decreasing PTH for 25(OH)D3 levels between 25 and 75 nmol/L regardless of vitamin D treatment. In an interaction model, the negative slope between 25(OH)D3 and PTH remained significant beyond 75 nmol/L in the absence of calcitriol. Increasing 25(OH)D3 was associated with significantly decreasing phosphate for 25(OH)D3 levels between 25 and 75 nmol/L regardless of vitamin D treatment and below 25 nmol/L in values of untreated patients. Calcium increased across the spectrum of 25(OH)D3 regardless of vitamin D treatment. Overall, 0.2% of 25(OH)D3 levels exceeded 250 nmol/L and 2.1% of calcium levels exceeded the normal range.

Conclusions: Vitamin D treatment in a real-world setting was safe and associated with lower PTH levels. Whether improved biochemical markers translate to a reduction in clinical endpoints warrants further study.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
ESKD 患者的维生素 D 状态和治疗;在实际环境中与改善 CKD-MBD 实验室参数的联系。
导言:在接受血液透析的患者中,维生素 D 不足很常见,但在监测或治疗方面却没有明确的指导。我们假设,25(OH)D3 水平的增加与磷酸盐、甲状旁腺激素(PTH)和碱性磷酸酶(ALP)的降低有关:2017年6月,对所有接受中心内血液透析的患者进行了基线25(OH)D3水平测量。直到 2021 年 2 月,每 6 周(磷酸盐、钙)或 12 周(25(OH)D3、PTH、ALP)测量一次实验室参数。2018 年 9 月,建议采用每周 5 万 IU 的治疗算法,直到足够为止,然后每月 5 万 IU。研究采用了包括线性样条效应、对数链接函数和随机效应在内的广义线性混合回归模型,以考察提高 25(OH)D3 水平对钙、磷酸盐、ALP 和 PTH 的影响:在 697 名参与者中,分别有 15% 和 57% 存在维生素 D 缺乏(25(OH)D3 < 25 nmol/L)和不足(25 至 74 nmol/L)。纳入多达 7272 个观察结果后发现,当 25(OH)D3 水平在 25 至 75 nmol/L 之间时,无论维生素 D 治疗方法如何,25(OH)D3 的增加与 PTH 的显著降低相关。在相互作用模型中,如果不使用降钙素三醇,25(OH)D3 和 PTH 之间的负斜率在超过 75 nmol/L 后仍然显著。无论维生素D治疗与否,当25(OH)D3水平在25至75nmol/L之间时,25(OH)D3的增加与磷酸盐的显著降低相关,而在未经治疗的患者中,25 nmol/L以下的数值与磷酸盐的显著降低相关。无论维生素 D 治疗与否,钙在 25(OH)D3 的范围内都会增加。0.2%的25(OH)D3水平超过250 nmol/L,2.1%的钙水平超过正常范围:结论:在真实世界环境中进行维生素 D 治疗是安全的,并能降低 PTH 水平。生化指标的改善是否会导致PTH水平的降低?
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American Journal of Nephrology
American Journal of Nephrology 医学-泌尿学与肾脏学
CiteScore
7.50
自引率
2.40%
发文量
74
审稿时长
4-8 weeks
期刊介绍: The ''American Journal of Nephrology'' is a peer-reviewed journal that focuses on timely topics in both basic science and clinical research. Papers are divided into several sections, including:
期刊最新文献
Off-label Use of Mycophenolate Mofetil in Immunoglobulin A Nephropathy: A Systematic Review and Meta-analysis. Urinary sodium excretion and kidney disease progression in IgA nephropathy: A cohort study. A risk prediction model for new-onset chronic kidney disease in the elderly. Long-term Efficacy and Safety of Upacicalcet in Japanese Hemodialysis Patients with Secondary Hyperparathyroidism: Open-label 52-week Study. Association between timing of vascular access creation and mortality in patients initiating hemodialysis: A nationwide cohort study in Japan.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1